Philip Morris International (PMI), the tobacco giant behind the popular Zyn nicotine pouch brand, is facing increased regulatory scrutiny in the United States. The product, a smokeless, flavored nicotine pouch placed between the gum and lip, has seen a surge in sales and popularity, particularly among younger adults.
This rapid growth has drawn attention from lawmakers and public health officials concerned about nicotine addiction. In early 2024, a group of U.S. Senators launched an investigation into PMI's marketing practices for Zyn, citing concerns over its appeal to youth. The company has stated its products are intended for adult smokers seeking alternatives.
The scrutiny comes as the U.S. Food and Drug Administration (FDA) continues to evaluate applications for marketing orders for oral nicotine pouches. The regulatory landscape for such smoke-free nicotine products remains complex and evolving.
While Zyn is manufactured by Swedish Match, a subsidiary of PMI, its market presence has sparked broader debates about next-generation nicotine products, their public health impact, and the strategies of major tobacco companies transitioning away from traditional cigarettes.
